JP6215970B2 - 注射可能なモルヒネ製剤 - Google Patents

注射可能なモルヒネ製剤 Download PDF

Info

Publication number
JP6215970B2
JP6215970B2 JP2015562121A JP2015562121A JP6215970B2 JP 6215970 B2 JP6215970 B2 JP 6215970B2 JP 2015562121 A JP2015562121 A JP 2015562121A JP 2015562121 A JP2015562121 A JP 2015562121A JP 6215970 B2 JP6215970 B2 JP 6215970B2
Authority
JP
Japan
Prior art keywords
morphine
formulation
months
formulations
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015562121A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512210A (ja
JP2016512210A5 (https=
Inventor
キュイン，アラン
オアロ，ディディエ
ロマン，ポーリン
Original Assignee
フレゼニウス カービ ドイチュラント ゲーエムベーハー
フレゼニウス カービ ドイチュラント ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フレゼニウス カービ ドイチュラント ゲーエムベーハー, フレゼニウス カービ ドイチュラント ゲーエムベーハー filed Critical フレゼニウス カービ ドイチュラント ゲーエムベーハー
Publication of JP2016512210A publication Critical patent/JP2016512210A/ja
Publication of JP2016512210A5 publication Critical patent/JP2016512210A5/ja
Application granted granted Critical
Publication of JP6215970B2 publication Critical patent/JP6215970B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
JP2015562121A 2013-03-14 2014-03-12 注射可能なモルヒネ製剤 Active JP6215970B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361785218P 2013-03-14 2013-03-14
US61/785,218 2013-03-14
PCT/EP2014/054831 WO2014140095A1 (en) 2013-03-14 2014-03-12 Injectable morphine formulations

Publications (3)

Publication Number Publication Date
JP2016512210A JP2016512210A (ja) 2016-04-25
JP2016512210A5 JP2016512210A5 (https=) 2017-06-01
JP6215970B2 true JP6215970B2 (ja) 2017-10-18

Family

ID=50288050

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015562121A Active JP6215970B2 (ja) 2013-03-14 2014-03-12 注射可能なモルヒネ製剤

Country Status (8)

Country Link
US (7) US9072781B2 (https=)
EP (2) EP2968132B1 (https=)
JP (1) JP6215970B2 (https=)
CN (2) CN109125254A (https=)
AU (1) AU2014230834B9 (https=)
BR (1) BR112015021586B1 (https=)
CA (1) CA2902343C (https=)
WO (1) WO2014140095A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014230834B9 (en) 2013-03-14 2017-08-31 Fresenius Kabi Deutschland Gmbh Injectable morphine formulations
WO2014140097A1 (en) 2013-03-14 2014-09-18 Becton Dickinson France S.A.S. Packaging system for oxygen-sensitive drugs
ES2988823T3 (es) 2014-12-03 2024-11-21 Csl Behring Ag Producto farmacéutico con mayor estabilidad que comprende inmunoglobulinas
US20170189352A1 (en) 2015-03-13 2017-07-06 Par Pharmaceutical, Inc. Epinephrine formulations
US9119876B1 (en) 2015-03-13 2015-09-01 Par Pharmaceutical, Inc. Epinephrine formulations
US11369700B2 (en) 2015-05-25 2022-06-28 IGL Pharma Inc. DOTMP kit formulations for radioisotopes
WO2016191413A1 (en) * 2015-05-25 2016-12-01 Iso Therapeutics Group, Llc Dotmp kit formulations for radioisotopes
US20180064703A1 (en) * 2016-09-02 2018-03-08 Sun Pharmaceutical Industries Ltd. Stable infusion dosage form of morphine
EP3515412B1 (en) * 2016-09-23 2025-04-23 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
WO2019183416A1 (en) 2018-03-23 2019-09-26 Nevakar Inc. Epinephrine compositions and containers
CN114207101B (zh) 2019-07-31 2024-05-31 埃科莱布美国股份有限公司 免用个人防护设备的脱灰剂组合物
US11806320B2 (en) * 2020-02-19 2023-11-07 Endo Ventures Limited Isoproterenol compositions and methods
US20240041866A1 (en) * 2020-12-18 2024-02-08 Fujifilm Toyama Chemical Co., Ltd. Pharmaceutical composition

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1048712A (en) 1912-02-23 1912-12-31 John Uri Lloyd Process of extracting, purifying, or excluding alkaloids and alkaloidal salts.
US2715627A (en) 1952-05-26 1955-08-16 Charles L Mehltretter Solvent extraction of opium alkaloids
US4071620A (en) 1977-01-10 1978-01-31 American Home Products Corporation Stabilization of oxygen sensitive dose forms
JPS56125876U (https=) 1980-02-23 1981-09-25
US4367738A (en) 1981-10-28 1983-01-11 Janssen Pharmaceutica Inc. Pre-filled syringe for abusable drugs
DE3376194D1 (en) 1982-10-08 1988-05-11 Terumo Corp Evacuated blood collecting device
US4998400A (en) 1986-03-22 1991-03-12 Material Engineering Technology Laboratory, Incorporated Medical fluid-filled plastic container and methods of making same
JPS6311160A (ja) 1986-07-02 1988-01-18 株式会社新素材総合研究所 薬液容器収納体及びその製造方法
US5723147A (en) 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
US5807572A (en) 1988-02-18 1998-09-15 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
US5030216A (en) 1989-12-15 1991-07-09 Alza Corporation Osmotically driven syringe
JP3630436B2 (ja) 1991-11-13 2005-03-16 株式会社創研 米からの活性酸素消去剤
GB9200219D0 (en) 1992-01-07 1992-02-26 Medimech Int Ltd Automatic injectors
AU5898794A (en) 1992-12-14 1994-07-04 Mallinckrodt Medical, Inc. Methods of producing prefilled delivery devices without exterior or interior contamination
CA2120197A1 (en) 1993-04-02 1994-10-03 Kenji Endo Stable aqueous dispersions containing liposomes
US5414049A (en) 1993-06-01 1995-05-09 Howmedica Inc. Non-oxidizing polymeric medical implant
SE9401986D0 (sv) 1994-06-08 1994-06-08 Pharmacia Ab New process for sterilization and articles sterilized thereby
US6196998B1 (en) 1994-12-12 2001-03-06 Becton Dickinson And Company Syringe and tip cap assembly
US5624402A (en) 1994-12-12 1997-04-29 Becton, Dickinson And Company Syringe tip cap
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
US6054584A (en) 1996-11-19 2000-04-25 The Board Of Regents Of The University And Community College System Of Neveda Process for extracting and purifying morphine from opium
SE9601348D0 (sv) 1996-04-10 1996-04-10 Pharmacia Ab Improved containers for parenteral fluids
JP3879017B2 (ja) 1996-06-17 2007-02-07 株式会社大塚製薬工場 重炭酸塩含有薬液容器包装体及びｐＨインジケーター
WO1998000159A1 (en) 1996-06-28 1998-01-08 Oxigene, Inc. Useful formulations of acid addition salt drugs
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
JPH10182687A (ja) 1996-10-21 1998-07-07 Bayer Yakuhin Kk アカルボースの貯蔵安定化法
AU735906B2 (en) 1996-12-16 2001-07-19 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College, The Blunt tip cannula with access pin
US5891467A (en) 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
AU6893898A (en) 1997-04-10 1998-10-30 Johns Hopkins University, The Gaz syringe and package therefor
JPH1147274A (ja) 1997-06-03 1999-02-23 Takeda Chem Ind Ltd ２室型注射器及び２室型注射器用接続具
AU1117599A (en) 1997-10-31 1999-05-24 Abbott Laboratories System for storing oxygen sensitive compositions
US6200627B1 (en) 1998-03-17 2001-03-13 Becton, Dickinson And Company Low silicone glass prefillable syringe
US6361524B1 (en) 1998-04-14 2002-03-26 Becton, Dickinson And Company Syringe assembly
US6217550B1 (en) 1998-07-29 2001-04-17 Becton, Dickinson And Company Single-use syringe
US6333087B1 (en) 1998-08-27 2001-12-25 Chevron Chemical Company Llc Oxygen scavenging packaging
AU6046900A (en) 1999-06-16 2001-01-02 Nastech Pharmaceutical Company, Inc Method for increasing the solubility of morphine and pharmaceutical compositionsprepared therefrom
US7137968B1 (en) 2000-03-13 2006-11-21 Nucryst Pharmaceuticals Corp. Transcutaneous medical device dressings and method of use
US6875400B2 (en) 2000-12-22 2005-04-05 Cryovac, Inc. Method of sterilizing and initiating a scavenging reaction in an article
JP2002253641A (ja) 2001-03-01 2002-09-10 Terumo Corp プレフィルドシリンジ用注射器包装体
EP1243524A3 (en) 2001-03-16 2004-04-07 Pfizer Products Inc. Pharmaceutical kit for oxygen-sensitive drugs
EP1241110A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Dispensing unit for oxygen-sensitive drugs
JP2003052819A (ja) 2001-08-10 2003-02-25 Seikagaku Kogyo Co Ltd 薬剤充填注射器包装物およびその滅菌または殺菌方法
CA2465436A1 (en) 2001-11-02 2003-05-15 Meridian Medical Technologies, Inc. A medicament container, a medicament dispensing kit for administering medication and a method for packaging the same
US6870273B2 (en) 2002-04-29 2005-03-22 Pmc-Sierra, Inc. High speed I/O pad and pad/cell interconnection for flip chips
JP2004057321A (ja) 2002-07-26 2004-02-26 Shionogi & Co Ltd 収着酸素が除去されたプラスチック容器
KR20050051685A (ko) 2002-10-08 2005-06-01 가부시키가이샤 오츠까 세이야꾸 고죠 서스펜더 형성 구조 및 이 구조를 갖는 약제 용기
US20040102476A1 (en) 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
WO2004058337A1 (en) 2002-12-23 2004-07-15 Medtronic, Inc. Multiple infusion section catheters, systems, and methods
EP1589902A1 (en) 2003-01-27 2005-11-02 Medtronic Vascular Connaught Improved packaging for stent delivery systems
JP2004229750A (ja) 2003-01-28 2004-08-19 Nipro Corp プレフィルドシリンジ及びそのバレルの製造方法
JP2006513938A (ja) 2003-03-25 2006-04-27 メドトロニック ヴァスキュラー コノート ステント及びステント運搬システムの包装
CA2811272C (en) 2003-04-08 2016-12-20 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
EP1616549B1 (en) 2003-04-23 2012-10-10 Otsuka Pharmaceutical Factory, Inc. Drug solution filling plastic ampoule and process for producing the same
US20040243214A1 (en) 2003-04-23 2004-12-02 Medtronic Vascular, Inc. Coated stent with protective packaging and method of using same
FR2855413B1 (fr) 2003-05-26 2005-12-30 Becton Dickinson France Seringue pre-remplie avec coiffe anti effraction
WO2005011638A2 (en) 2003-08-05 2005-02-10 Zentiva, A. S. Methods for the stabilization of atorvastatin
US20050085785A1 (en) 2003-10-17 2005-04-21 Sherwin Shang High impact strength film and non-pvc containing container and pouch and overpouch
US20050228336A1 (en) 2004-04-07 2005-10-13 Preston Keusch Electrically assisted lidocaine and epinephrine delivery device having extended shelf-stability
JP4759232B2 (ja) 2004-07-02 2011-08-31 テルモ株式会社 包装されたプレフィルドシリンジの製造方法
WO2006008651A1 (en) 2004-07-16 2006-01-26 Pfizer Products Inc. Pharmaceutical package for simultaneously maintaining low moisture and low oxygen levels
ATE422852T1 (de) 2004-12-08 2009-03-15 Perfecseal Inc Sterilisierbares paket mit hoher sauerstoffbarriere
WO2006118034A1 (ja) 2005-04-28 2006-11-09 Otsuka Pharmaceutical Factory, Inc. 薬液容器収容体およびその製造方法
EP1930040B1 (en) 2005-08-22 2011-03-16 Nipro Corporation Prefilled syringe
BRPI0503734A (pt) 2005-08-23 2007-04-27 Cristalia Prod Quimicos Farm composição farmacêutica na forma de solução injetável de morfina pronta para uso e forma de dosagem unitária de morfina para administração epidural ou intratecal
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
JP2008067989A (ja) 2006-09-15 2008-03-27 Terumo Corp プレフィルドシリンジ用収納容器および包装されたプレフィルドシリンジ
GB0619060D0 (en) 2006-09-27 2006-11-08 Glaxosmithkline Biolog Sa Novel process
HUE027439T2 (hu) 2006-10-27 2016-10-28 Otsuka Pharma Factory Inc Hatóanyag-oldatot tartalmazó csomagolás csökkentett oldottoxigén-tartalommal
JP5411422B2 (ja) 2007-01-31 2014-02-12 関西電力株式会社 バイポーラ型半導体装置、その製造方法およびツェナー電圧の制御方法
US20080308444A1 (en) 2007-06-13 2008-12-18 Baxter International Inc. Packaging system and method of alerting a practitioner
US8002737B2 (en) 2007-10-04 2011-08-23 Hyprotek, Inc. Mixing/administration syringe devices, protective packaging and methods of protecting syringe handlers
JP5438896B2 (ja) 2007-12-27 2014-03-12 大日本印刷株式会社 プレフィルドシリンジ用の包装袋
US8623401B2 (en) * 2008-03-27 2014-01-07 Fenwafe Inc. Wafer formulation
FR2931681B1 (fr) 2008-05-30 2011-11-25 Becton Dickinson France Seringue a embout universel
US9095324B2 (en) 2008-06-20 2015-08-04 Boston Scientific Scimed, Inc. Package assembly
JP5587597B2 (ja) 2008-12-19 2014-09-10 藤森工業株式会社 包装体
JP5332958B2 (ja) 2009-06-29 2013-11-06 大日本印刷株式会社 プレフィルドシリンジ包装体及びプレフィルドシリンジ用パック
GB2471726B (en) 2009-07-10 2013-09-11 Oval Medical Technologies Ltd A pre-filled syringe including an oxygen absorber
CN102639118B (zh) 2009-07-22 2015-07-29 格吕伦塔尔有限公司 氧化稳定的抗干扰剂型
US9333288B2 (en) 2011-09-30 2016-05-10 Becton Dickinson France, S.A.S. Attachable plunger rod and associated packaging
AU2014230834B9 (en) 2013-03-14 2017-08-31 Fresenius Kabi Deutschland Gmbh Injectable morphine formulations
WO2014140097A1 (en) 2013-03-14 2014-09-18 Becton Dickinson France S.A.S. Packaging system for oxygen-sensitive drugs

Also Published As

Publication number Publication date
US9192608B2 (en) 2015-11-24
US20230414604A1 (en) 2023-12-28
US20190167665A1 (en) 2019-06-06
WO2014140095A1 (en) 2014-09-18
US20150246036A1 (en) 2015-09-03
US20250228846A1 (en) 2025-07-17
JP2016512210A (ja) 2016-04-25
EP2968132A1 (en) 2016-01-20
AU2014230834A1 (en) 2015-09-10
AU2014230834B9 (en) 2017-08-31
US20140275144A1 (en) 2014-09-18
CA2902343A1 (en) 2014-09-18
US20200345720A1 (en) 2020-11-05
US10213424B2 (en) 2019-02-26
US20160175297A1 (en) 2016-06-23
CA2902343C (en) 2022-08-02
CN109125254A (zh) 2019-01-04
AU2014230834B2 (en) 2017-08-03
EP3143988A1 (en) 2017-03-22
EP2968132B1 (en) 2017-09-13
US9072781B2 (en) 2015-07-07
CN104042565A (zh) 2014-09-17
BR112015021586A2 (pt) 2017-07-18
BR112015021586B1 (pt) 2023-01-31

Similar Documents

Publication Publication Date Title
JP6215970B2 (ja) 注射可能なモルヒネ製剤
ES2655863T3 (es) Formulaciones para administración parenteral de compuestos y sus usos
ES2691309T3 (es) Soluciones orales estables para API combinados
US20080064743A1 (en) Dry powder compound formulations and uses thereof
JP2024506861A (ja) 物質使用障害の治療のための隔離化合物及びその使用
TW200526195A (en) Compositions comprising cyclohexylamines and aminoadamantanes
US20250195412A1 (en) Pharmaceutical formulations of r-ketamine
HK1233500A1 (en) Injectable morphine formulations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151026

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170313

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20170313

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20170427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170808

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170905

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170921

R150 Certificate of patent or registration of utility model

Ref document number: 6215970

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250